Home
News Intelligence
Laboratorio Reig Jofre S.A.

Laboratorio Reig Jofre S.A.

Healthcare · Biotechnology

BME:RJF

Get alerts

Plain English summaries when Laboratorio Reig Jofre S.A. announces news.

Latest announcement

Financial results

Jul 31, 2026

REIG JOFRE reports €17.9 million EBITDA for H1 2026 as Toledo antibiotics line starts production

REIG JOFRE reported higher EBITDA and net income in H1 2026, while its new penicillin-based injectable antibiotics line in Toledo received regulatory approval and began production.

View summary and FAQs

Announcement Summary
Investor FAQs
Video
Interactive Chat

Latest by type

Financial results: REIG JOFRE reports €17.9 million EBITDA for H1 2026 as Toledo antibiotics line starts production Jul 31, 2026

Announcements

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

About, from recent announcements

Laboratorio Reig Jofre S.A. develops, manufactures and markets essential healthcare solutions, including prescription products and hospital anti-infectives. It reported revenue of €168.5 million and consolidated EBITDA of €17.9 million for H1 2026, and announced regulatory approval and the start-up of a new antibiotics production line in Toledo. It also launched dalbavancin in Europe and reported that VINCOBIOSIS® had been recognised at the 2nd Aesthetic Technology Awards.

Sources: 3 announcements

Laboratorio Reig Jofre S.A.

Get alerts

REIG JOFRE reports €17.9 million EBITDA for H1 2026 as Toledo antibiotics line starts production

Latest by type

Announcements

REIG JOFRE begins European marketing of dalbavancin across nine countries

REIG JOFRE Receives Recognition for VINCOBIOSIS® at Aesthetic Technology Awards

REIG JOFRE reports Q1 2026 revenue decrease as EBITDA rises 1%

REIG JOFRE reports €331.1M revenue for 2025 as Toledo upgrades weigh on antibiotics

REIG JOFRE announces increase in Leanbio stake to 85% for 3.5 million euros